CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress
-70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma…
The Tech Interactive Announces Seismic Valley: The Earthquake Experience, Coming Summer 2027
Islamic Finance Takes Center Stage as a Driver of Sustainable Economic Growth at Global Forum
OMP and Eastman Show Decision Velocity in Practice at Gartner Supply Chain Planning Summit 2026